Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
ICLR vs MEDP
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
ICLR vs MEDP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $9.51B | $12.11B |
| Revenue (TTM) | $8.10B | $2.68B |
| Net Income (TTM) | $599M | $460M |
| Gross Margin | 26.9% | 29.1% |
| Operating Margin | 12.2% | 21.0% |
| Forward P/E | 10.7x | 25.0x |
| Total Debt | $3.60B | $250M |
| Cash & Equiv. | $539M | $497M |
ICLR vs MEDP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| ICON Public Limited… (ICLR) | 100 | 73.9 | -26.1% |
| Medpace Holdings, I… (MEDP) | 100 | 456.8 | +356.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ICLR vs MEDP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ICLR is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.64, Low D/E 37.8%, current ratio 1.26x
- Lower P/E (10.7x vs 25.0x)
MEDP carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.21
- Rev growth 20.0%, EPS growth 21.0%, 3Y rev CAGR 20.1%
- 14.3% 10Y total return vs ICLR's 90.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs ICLR's 2.0% | |
| Value | Lower P/E (10.7x vs 25.0x) | |
| Quality / Margins | 17.2% margin vs ICLR's 7.4% | |
| Stability / Safety | Beta 1.21 vs ICLR's 1.64 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +41.0% vs ICLR's -10.1% | |
| Efficiency (ROA) | 24.8% ROA vs ICLR's 3.6%, ROIC 154.9% vs 6.5% |
ICLR vs MEDP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ICLR vs MEDP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MEDP leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ICLR is the larger business by revenue, generating $8.1B annually — 3.0x MEDP's $2.7B. MEDP is the more profitable business, keeping 17.2% of every revenue dollar as net income compared to ICLR's 7.4%. On growth, MEDP holds the edge at +26.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $8.1B | $2.7B |
| EBITDAEarnings before interest/tax | $1.4B | $577M |
| Net IncomeAfter-tax profit | $599M | $460M |
| Free Cash FlowCash after capex | $996M | $745M |
| Gross MarginGross profit ÷ Revenue | +26.9% | +29.1% |
| Operating MarginEBIT ÷ Revenue | +12.2% | +21.0% |
| Net MarginNet income ÷ Revenue | +7.4% | +17.2% |
| FCF MarginFCF ÷ Revenue | +12.3% | +27.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +0.6% | +26.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -98.7% | +16.6% |
Valuation Metrics
ICLR leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 13.1x trailing earnings, ICLR trades at a 53% valuation discount to MEDP's 27.7x P/E. Adjusting for growth (PEG ratio), MEDP offers better value at 0.87x vs ICLR's 1.86x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $9.5B | $12.1B |
| Enterprise ValueMkt cap + debt − cash | $12.6B | $11.9B |
| Trailing P/EPrice ÷ TTM EPS | 13.06x | 27.75x |
| Forward P/EPrice ÷ next-FY EPS est. | 10.73x | 24.96x |
| PEG RatioP/E ÷ EPS growth rate | 1.86x | 0.87x |
| EV / EBITDAEnterprise value multiple | 7.92x | 21.07x |
| Price / SalesMarket cap ÷ Revenue | 1.15x | 4.79x |
| Price / BookPrice ÷ Book value/share | 1.09x | 27.27x |
| Price / FCFMarket cap ÷ FCF | 8.50x | 17.76x |
Profitability & Efficiency
MEDP leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $6 for ICLR. ICLR carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to MEDP's 0.55x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs MEDP's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +6.3% | +120.9% |
| ROA (TTM)Return on assets | +3.6% | +24.8% |
| ROICReturn on invested capital | +6.5% | +154.9% |
| ROCEReturn on capital employed | +7.8% | +65.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.38x | 0.55x |
| Net DebtTotal debt minus cash | $3.1B | -$247M |
| Cash & Equiv.Liquid assets | $539M | $497M |
| Total DebtShort + long-term debt | $3.6B | $250M |
| Interest CoverageEBIT ÷ Interest expense | 3.96x | — |
Total Returns (Dividends Reinvested)
MEDP leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MEDP five years ago would be worth $26,697 today (with dividends reinvested), compared to $5,523 for ICLR. Over the past 12 months, MEDP leads with a +41.0% total return vs ICLR's -10.1%. The 3-year compound annual growth rate (CAGR) favors MEDP at 26.5% vs ICLR's -13.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -34.0% | -25.7% |
| 1-Year ReturnPast 12 months | -10.1% | +41.0% |
| 3-Year ReturnCumulative with dividends | -34.4% | +102.4% |
| 5-Year ReturnCumulative with dividends | -44.8% | +167.0% |
| 10-Year ReturnCumulative with dividends | +90.2% | +1425.7% |
| CAGR (3Y)Annualised 3-year return | -13.1% | +26.5% |
Risk & Volatility
MEDP leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MEDP is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than ICLR's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MEDP currently trades 67.4% from its 52-week high vs ICLR's 59.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.64x | 1.21x |
| 52-Week HighHighest price in past year | $211.00 | $628.92 |
| 52-Week LowLowest price in past year | $66.57 | $284.48 |
| % of 52W HighCurrent price vs 52-week peak | +59.0% | +67.4% |
| RSI (14)Momentum oscillator 0–100 | 62.8 | 41.4 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 371K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ICLR as "Buy" and MEDP as "Hold". Consensus price targets imply 22.2% upside for ICLR (target: $152) vs 17.7% for MEDP (target: $499).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $152.13 | $498.86 |
| # AnalystsCovering analysts | 30 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.3% | +7.6% |
MEDP leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ICLR leads in 1 (Valuation Metrics).
ICLR vs MEDP: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is ICLR or MEDP a better buy right now?
For growth investors, Medpace Holdings, Inc.
(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus 2. 0% for ICON Public Limited Company (ICLR). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 7x forward), making it the more compelling value choice. Analysts rate ICON Public Limited Company (ICLR) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ICLR or MEDP?
On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.
1x versus Medpace Holdings, Inc. at 27. 7x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 78x versus ICON Public Limited Company's 1. 53x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ICLR or MEDP?
Over the past 5 years, Medpace Holdings, Inc.
(MEDP) delivered a total return of +167. 0%, compared to -44. 8% for ICON Public Limited Company (ICLR). Over 10 years, the gap is even starker: MEDP returned +1426% versus ICLR's +90. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ICLR or MEDP?
By beta (market sensitivity over 5 years), Medpace Holdings, Inc.
(MEDP) is the lower-risk stock at 1. 21β versus ICON Public Limited Company's 1. 64β — meaning ICLR is approximately 35% more volatile than MEDP relative to the S&P 500. On balance sheet safety, ICON Public Limited Company (ICLR) carries a lower debt/equity ratio of 38% versus 55% for Medpace Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ICLR or MEDP?
By revenue growth (latest reported year), Medpace Holdings, Inc.
(MEDP) is pulling ahead at 20. 0% versus 2. 0% for ICON Public Limited Company (ICLR). On earnings-per-share growth, the picture is similar: ICON Public Limited Company grew EPS 28. 8% year-over-year, compared to 21. 0% for Medpace Holdings, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ICLR or MEDP?
Medpace Holdings, Inc.
(MEDP) is the more profitable company, earning 17. 8% net margin versus 9. 6% for ICON Public Limited Company — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus 13. 3% for ICLR. At the gross margin level — before operating expenses — MEDP leads at 30. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ICLR or MEDP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 78x versus ICON Public Limited Company's 1. 53x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 7x forward P/E versus 25. 0x for Medpace Holdings, Inc. — 14. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ICLR: 22. 2% to $152. 13.
08Which pays a better dividend — ICLR or MEDP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ICLR or MEDP better for a retirement portfolio?
For long-horizon retirement investors, Medpace Holdings, Inc.
(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), +1426% 10Y return). ICON Public Limited Company (ICLR) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1426%, ICLR: +90. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ICLR and MEDP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ICLR is a small-cap deep-value stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.